---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-029956"
form_type: "8-K"
ticker: "CLSDQ"
cik: "0001539029"
company_name: "Clearside Biomedical, Inc."
filed_at: "2024-03-12T23:59:59+00:00"
generated_at: "2026-06-04T23:00:07.861650+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Clearside Biomedical Q4 2023 net loss narrows to $4.8M; cash runway to Q3 2025

## Summary
- Net loss Q4 2023 of $4.8M ($0.08/shr) improved from $9.7M loss ($0.16/shr) in Q4 2022.
- License revenue Q4 2023 of $6.3M, up from $0.3M, driven by $5M BioCryst upfront and $1M Aura milestone.
- Cash $28.9M at Dec 31; subsequent $15M equity offering extends runway into Q3 2025.
- Phase 2b ODYSSEY wet AMD trial topline data expected Q3 2024; randomization completed Dec 2023.
- Full year 2023 net loss $32.5M ($0.53/shr) vs $32.9M ($0.55/shr) in 2022.

## SEC filing metadata
- accession: 0000950170-24-029956
- form_type: 8-K
- ticker: CLSDQ
- cik: 0001539029
- company_name: Clearside Biomedical, Inc.
- filed_at: 2024-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1539029/000095017024029956/0000950170-24-029956-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1539029/000095017024029956/clsd-20240312.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-029956
- JSON: https://secwatch.observer/filing/0000950170-24-029956.json
- Plain text: https://secwatch.observer/filing/0000950170-24-029956.txt

## Key facts
- Earnings Releases
  Clearside Biomedical, Inc. reported the fourth quarter and year ended December 31, 2023 results: revenue $6.3 million, net income Net loss for the fourth quarter of 2023 was $4.8 million, EPS $0.08 per share.
  - Period: the fourth quarter and year ended December 31, 2023
  - Revenue: $6.3 million
  - Net income: Net loss for the fourth quarter of 2023 was $4.8 million
  - EPS: $0.08 per share
  - Result: reported results
  source text: the first patient in the CoMpass trial in December 2023. Fourth Quarter 2023 Financial Results • License Revenue: License and other revenue for the fourth quarter of 2023 was $6.3 million, compared to $0.3 million for the fourth quarter of 2022. The $6.0 million increase was primarily attributable to the receipt of $5.0 million in an upfront license fee from
  evidence_url: https://www.sec.gov/Archives/edgar/data/1539029/000095017024029956/0000950170-24-029956-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.